Discussion on stakeholders behind unfair drug pricing: A scoping review

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F70883521%3A28120%2F23%3A63564358" target="_blank" >RIV/70883521:28120/23:63564358 - isvavai.cz</a>

Result on the web

<a href="https://www.cjournal.cz/files/492.pdf" target="_blank" >https://www.cjournal.cz/files/492.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.7441/joc.2023.03.01" target="_blank" >10.7441/joc.2023.03.01</a>

Result language

angličtina

Original language name

Discussion on stakeholders behind unfair drug pricing: A scoping review

Original language description

An unsettling issue for people worldwide has been the rise in medicine prices. The news routinely reports on surprising drug price increases; however, the general public isless informed about the real reason for increasing medicine prices. Although there are a number of parties involved in the drug price increase, it is unclear to whom the increase can be directly attributed. This study used the scoping review method, to map the literature on the topic. It answers a research question concerning stakeholder responsibility for increased drug prices. To do so, the authors conducted a literature survey of different scientific research databases between 2018 to 2022, using two key phrases: “unfair drug price” and “drug price stakeholders.” In the study, a total of 26 papers were full-text reviewed out of 323 papers that were initially identified. The cost-effectiveness of new medications that must go through the pricing and reimbursement procedure is routinely assessed by the pharmaceutical industry. However, because there is a data gap, it is impossible to assess the relationship between drug costs and demand over a longer time period, to identify the drugs that are not covered by health insurance, or to determine the role of health insurance in rising drug prices. Even so, the scoping review reveals more evidence that pharmaceutical corporations have the ability to determine prices, undermining the idea that the health insurance industry is the primary cause of price increases.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

50204 - Business and management

Project

—

Continuities

S - Specificky vyzkum na vysokych skolach

Publication year

2023

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Journal of Competitiveness

ISSN

1804-171X

e-ISSN

1804-1728

Volume of the periodical

15

Issue of the periodical within the volume

3

Country of publishing house

CZ - CZECH REPUBLIC

Number of pages

16

Pages from-to

3-18

UT code for WoS article

001088356700001

EID of the result in the Scopus database

2-s2.0-85174901110